Source link : https://newshealth.biz/health-news/nsclc-study-makes-compelling-case-to-continue-egfr-inhibitor-beyond-progression/
(MedPage Today) — Patients with EGFR-mutated non-small cell lung cancer (NSCLC) who progressed on first-line osimertinib (Tagrisso) had better progression-free survival (PFS) in second line when they continued osimertinib plus chemotherapy, a… Source link : https://www.medpagetoday.com/meetingcoverage/iaslc/117361 Author : Publish date : 2025-09-08 18:35:00 Copyright for syndicated content belongs to the linked Source.
The post NSCLC Study Makes ‘COMPELling’ Case to Continue EGFR Inhibitor Beyond Progression first appeared on News Health.
—-
Author : News Health
Publish date : 2025-09-08 18:35:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8